Citigroup Lowers Evolent Health (NYSE:EVH) Price Target to $18.00

Evolent Health (NYSE:EVH) had its target price decreased by research analysts at Citigroup from $21.00 to $18.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the technology company’s stock. Citigroup’s price target indicates a potential upside of 42.97% from the stock’s current price.

EVH has been the topic of a number of other reports. Oppenheimer decreased their target price on Evolent Health from $34.00 to $28.00 and set an “outperform” rating on the stock in a report on Monday, November 18th. Barclays lowered their price objective on Evolent Health from $39.00 to $19.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. JPMorgan Chase & Co. cut their price target on shares of Evolent Health from $45.00 to $15.00 and set an “overweight” rating for the company in a report on Friday, November 22nd. Stephens downgraded shares of Evolent Health from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $38.00 to $16.00 in a research report on Friday, November 8th. Finally, Needham & Company LLC initiated coverage on Evolent Health in a research note on Friday. They issued a “buy” rating and a $15.00 price objective on the stock. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $23.92.

Evolent Health Stock Down 0.1 %

Evolent Health stock traded down $0.01 during mid-day trading on Friday, reaching $12.59. The company’s stock had a trading volume of 986,027 shares, compared to its average volume of 1,382,427. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. Evolent Health has a 12 month low of $10.53 and a 12 month high of $35.00. The business’s 50 day simple moving average is $13.13 and its 200 day simple moving average is $21.09. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of -13.84 and a beta of 1.45.

Institutional Investors Weigh In On Evolent Health

Institutional investors and hedge funds have recently made changes to their positions in the stock. Covestor Ltd grew its stake in Evolent Health by 138.1% during the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock worth $40,000 after purchasing an additional 826 shares during the period. GAMMA Investing LLC grew its position in shares of Evolent Health by 5,365.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock worth $45,000 after buying an additional 1,556 shares during the period. Quarry LP acquired a new stake in shares of Evolent Health during the 2nd quarter worth approximately $32,000. Canada Pension Plan Investment Board bought a new stake in shares of Evolent Health in the 2nd quarter valued at $61,000. Finally, Quest Partners LLC acquired a new position in shares of Evolent Health during the 2nd quarter valued at $87,000.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.